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INTRODUCTION
Despite progress in childhood ALL, outcomes remain poor after
relapse. Patients with very early marrow relapse (less than 18 months
from diagnosis) have fared worse with a 5-year survival of about
15% [1]. In studies of patients with early marrow relapse, only those
achieving complete remission (CR) after a single treatment block
survived [2,3]. Children’s Oncology Group (COG) studies showed a
remission reinduction rate of about 70% after one treatment block
for very early and early first marrow relapse [2,3]. Patients with very
early relapsed ALL (less than 18 months from diagnosis) had low
reinduction rate of 45% [3]. Review of the experience at Therapeutic
Advances in Childhood Leukemia (TACL) institutions found a
remission reinduction rate of 78% for very early and 86% CR for
early first marrow relapse [4]. Remissions were more difficult to
achieve in children with multiple recurrences. The TACL group
observed low remission rates of 44%, 27%, and 12% for third,
fourth, and further therapeutic attempts, respectively [4]. In that
study disease-free survival (DFS) of patients in CR3 or above was
only 15% at 5 years, indicating the poor outcome of multiple
relapsed patients [4]. Since limited progress in the treatment of bone
marrow relapsed ALL has been documented over the past 20 years
[1] and outcomes remain poor, new therapeutic strategies for
relapsed childhood leukemia are urgently needed.
The TACL consortium chose to study bortezomib as a new agent
in this population based on promising preclinical activity and
success in other hematopoietic malignancies. Bortezomib is a
selective inhibitor of the ubiquitin proteasome pathway (UPP),
which is an essential pathway for the degradation of most
proteins in eukaryotic cells [5]. Important regulatory proteins
affected by inhibition of the UPP system include NF-kB, p53, Bax,
p27, and p21 [6]. Proteasome inhibition may sensitize malignant
hematologic cells to apoptosis induced by both radiation and
chemotherapy [7–9]. Bortezomib has received FDA approval
for use in adults with multiple myeloma and relapsed NHL [10].
Preclinical studies did show some activity of single agent
bortezomib in ALL [11]. Unfortunately, clinical studies showed
very little activity of the single agent bortezomib in either adults [12]
or children [13] with acute leukemia.
Bortezomib may have enhanced anti-leukemic activity when
used in combination with chemotherapy. Horton et al. [14]
have shown that bortezomib and dexamethasone have synergistic
anti-leukemia interactions in vitro, and bortezomib had additive
anti-leukemia effects when combined with asparaginase, vincris-
tine, doxorubicin, or cytosine arabinoside. A multiply relapsed
child with ALL had transient clinical response to bortezomib and
Background. Outcomes remain poor for children after relapse of
acute lymphoblastic leukemia (ALL), especially after early marrow
relapse. Bortezomib is a proteasome inhibitor with in vitro synergy
with corticosteroids and clinical activity in human lymphoid
malignancies. Procedure. This is a Phase I study of escalating
doses bortezomib administered days 1, 4, 8, and 11, added to 4-drug
induction chemotherapy with vincristine, dexamethasone, pegylated
L-asparaginase, and doxorubicin (VXLD) in children with relapsed
ALL. Results. Ten patients were enrolled, five in first marrow relapse,
and five in second relapse. Four patients were enrolled at dose level
1 (bortezomib 1 mg/m2). One patient was not evaluable for toxicity
because of omitted dexamethasone doses. No dose-limiting toxicity
(DLT) was observed. Six patients were enrolled at dose level 2
(bortezomib 1.3 mg/m2). One patient had dose-limiting hypophos-
phatemia and rhabdomyolysis after 1 dose of bortezomib, and died
from a diffuse zygomyces infection on day 17. Five additional
patients were enrolled with no subsequent DLTs. As planned, no
further dose escalation was pursued. The regimen had predictable
toxicity related to the chemotherapy drugs. Two patients had mild
peripheral neuropathy (grades 1 and 2). Six of nine evaluable
patients (67%) achieved a complete response (CR), and one had a
bone marrow CR with persistent central nervous system leukemia.
Conclusions. The combination of bortezomib (1.3 mg/m2) with
VXLD is active with acceptable toxicity in pretreated pediatric
patients with relapsed ALL. We are expanding the 1.3 mg/m2
cohort for a phase II estimate of response. Study registered at
ClinicalTrials.gov (http://clinicaltrials.gov/ct2/show/NCT00440726).
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dexamethasone [15]. In a phase I adult acute myeloid leukemia
(AML), Attar et al. [16] have shown that the combination of
bortezomib with idarubicin and cytosine arabinoside resulted in
61% CR’s and an additional 10% with CR’s but incomplete platelet
recovery (CRp).
Based on these studies, we added bortezomib to a standard
chemotherapy platform of vincristine, dexamethasone, pegylated
L-asparaginase (PEG-asparaginase), and doxorubicin (VXLD)
platform. In a phase I/II study, we sought to determine whether
the previously defined single agent dose of bortezomib is tolerable in
this context and to estimate a phase II response rate in second relapse
patients. The phase I part of this study is reported here.
PATIENTS AND METHODS
This study was approved by the Institutional Review Boards
(IRBs) of all participating TACL centers. An independent Data
Safety Monitoring Committee at Children’s Hospital of Los
Angeles monitored study progress.
Eligibility
Individual and/or parental informed consent was obtained from
all subjects as per local and federal requirements. Eligible patients
were21 years of age when originally diagnosed and1 year of age
at relapse. They had relapsed B-precursor or T cell ALL with25%
bone marrow blasts by morphology. CNS involvement was allowed.
During the phase I portion of the trial, patients were required to have
at least one prior treatment attempt, with no limit placed on the
number of prior treatment regimens. Patients were eligible after
allogeneic stem cell transplant as long as they were not being treated
actively for graft-versus-host-disease.
Karnofsky or Lansky scores 50 for patients older than 10 years
of age, or 10 years of age or younger, respectively, were required at
study entry. Allergy to asparaginase products, boron or mannitol,
prior exposure to 350 mg/m2 of anthracycline (in doxorubicin
equivalent dosing), or left ventricular fractional shortening less than
30% excluded participation. Other exclusion criteria were: serum
creatinine more than the upper limit of normal (ULN) for age; direct
bilirubin >1.5 times the institutional ULN; ALT >4 times ULN;
history of pancreatitis; serum amylase or lipase >2 times ULN; or
active uncontrolled infection. As neuropathy has been described
both for bortezomib and vincristine, patients with pre-existing
grade 2 motor or sensory neuropathy were also excluded.
Treatment and Dose Escalation
The treatment regimen is shown in Table I. Only 1 course of
therapy was planned. Bortezomib dose escalation included dose
levels of 1 mg/m2/dose (starting dose level) and 1.3 mg/m2/dose
(maximum planned dose level). De-escalation of bortezomib to
0.7 mg/m2/dose was planned if dose-limiting toxicity (DLT) was
observed at the starting dose level. No dose escalation of the
other chemotherapy agents was planned. Originally, CNS therapy
included only intrathecal chemotherapy on days 1 and 15 regardless
of CNS status. After four patients were enrolled and a patient with
CNS involvement did not clear the CSF, weekly triple intrathecal
chemotherapy was introduced for patients with CNS disease.
Patients were enrolled in groups of three patients, with dose
escalation following a standard 3þ 3 patient cohort escalation
design [17]. Briefly, 0/3 DLTs would allow escalation, 1/3 DLTs
required expanding to six patients, 1/6 DLTs allowed escalation,2
DLTs required de-escalation, and the maximum tolerated dose
(MTD) was the highest dose administered at which no more than 1/6
DLTs was observed. Dose escalation was based on DLTs occurring
during the single planned course of therapy.
Toxicity was graded using the CTCAE criteria, version 3.0
(http://ctep.cancer.gov). DLT was defined as any of the following
toxicities deemed by the investigator as possibly, probably, or
definitely attributable to bortezomib: grade 3 sensory neuropathy
or neuropathic pain; marrow hypoplasia (less than 10% cellularity)
which continued 6 weeks from the start of the course; grade 4 non-
hematologic toxicity excluding infection (septic shock, typhlitis),
fever and neutropenia, fatigue, electrolyte abnormalities, hyper- or
hypoglycemia, nausea or vomiting, or AST, ALT, or bilirubin
elevations that returned to grade 1 by the time of blood count
recovery following completion of the course.
Bortezomib was immediately discontinued for any DLT. Patients
could continue with the remainder of the backbone therapy
excluding bortezomib. PEG-asparaginase was to be discontinued
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TABLE I. Treatment Regimen
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for anaphylaxis or systemic allergic reactions, symptomatic
pancreatitis, significant bleeding, or significant thrombosis. No
modification of PEG-asparaginase or dexamethasone for hyper-
glycemia was planned.
Response Evaluation
Bone marrow aspirate/biopsy and CBC to assess response were
done on day 29. A bone marrow procedure was not required if the
patient has an absolute blast count (ABC) greater than or equal to
2,500/ml in the peripheral blood on day 29. If the marrow was
hypoplastic and peripheral blood counts had not recovered to
absolute neutrophil count (ANC) >750/ml and a platelet count
>75,000/ml, a repeat marrow aspiration and complete blood count
were required weekly until recovery or progression. If the patient
had 5% lymphoblasts in the bone marrow (M1 marrow) but did
not achieve an ANC >750/ml and a platelet count >75,000/ml, CBC
was repeated weekly until count recovery or relapse.
The following definitions of response were used: CR—M1
(<5% blasts) bone marrow with no evidence of circulating blasts or
extramedullary disease and with recovery of peripheral counts
(absolute neutrophil count (ANC) >750/ml and platelet count
>75,000/ml); CR without platelet recovery (CRp), M1 bone marrow
with no circulating blasts or extramedullary disease and recovery of
ANC >750/ml, but insufficient recovery of platelets (<75,000/ml);
partial remission (PR), complete disappearance of circulating blasts
and achievement of M2 (5–25% blasts) marrow status, without new
sites of extramedullary disease, and with recovery of absolute
neutrophil counts (ANC >750/ml); stable disease (SD), does not
satisfy the criterion for PD, or has recovery of ANC >750/ml but
fails to qualify for CR, CRp, or PR; progressive disease (PD), an
increase of at least 25% in the absolute number of circulating
leukemic cells, development of new sites of extramedullary disease,
or other laboratory or clinical evidence of PD, with or without
recovery of ANC or platelets. Minimal residual disease (MRD) was
not evaluated as a part of this study.
RESULTS
Patients and Dose Escalation
A total of 10 patients were enrolled in the phase I portion of this
study (Table II). Therewere two males and eight females. 18 months,
one patient age was 9.8 years (range 3.3–16.4 years). Nine patients
had B-precursor ALL and one patient had T-cell ALL. Five patients
were treated in first relapse, (very early relapse <18 months, one
patient; early relapse 18–36 months, one patient; late relapse
>36 months, three patients). Five patients were in second relapse.
None of the patients had primary refractory disease, and none had
prior stem–cell transplantation.
A total of four patients were treated on dose-level 1 (bortezomib
1 mg/m2/dose) (Table II). The third patient enrolled at this dose level
did not receive the correct doses of dexamethasone, was considered
incompletely evaluable for toxicity and not evaluable for response.
This patient was removed from further protocol therapy after day 8
and replaced to ensure a total of three fully evaluable patients. No
DLT was seen, so escalation to dose level 2 was initiated.
A total of six patients were then enrolled into dose level 2
(bortezomib 0.3 mg/m2/dose) (Table II). The first patient on this
dose level suffered DLT immediately after the first dose of
bortezomib. Based on the rule that 1/3 DLTs required expanding
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to six patients, an additional five patients were enrolled to that dose
level. No further DLT was seen and dose level 2 was deemed
tolerable. Since no further escalation of bortezomib was planned,
the phase I portion of the study was completed and dose level 2
(1.3 mg/m2/dose) was selected for further Phase II evaluation.
Toxicity
Details of the regimen-related toxicity are shown in
Table III. Patient T0015 was enrolled on the study at dose level 2
(1.3 mg/m2/day). The patient had received the first dose of
vincristine, bortezomib, and doxorubicin, but had not yet received
dexamethasone. Seventy minutes after the bortezomib she devel-
oped rigors, pain, hypotension, hyperpyrexia, and loss of conscious-
ness. She experienced grade 4 hypophosphatemia, and grade 3
myositis (rhabdomyolysis) with elevated creatine phosphokinase,
aldolase, and myoglobinuria. The patient did not receive additional
bortezomib. The patient recovered from this toxicity with the
exception of continued grade 1 hypophosphatemia. This patient
suffered hypophosphatemia during her original diagnosis and again
at relapse, suggesting that the hypophosphatemia may not have been
regimen-related. However, this constellation of symptoms was
determined to be a DLT. The patient continued with the chemo-
therapy backbone of the regimen (excluding bortezomib) and
expired from disseminated zygomyces infection on day 17. No other
DLT or regimen-associated mortality was seen on this part of the
study.
As expected all patients suffered hematologic grade 4 toxicity.
However, there was no prolonged bone marrow aplasia. Responding
patients achieved platelet >75,000/ml at median day 34 (range 27–
42) and ANC >750/ml at median day 41 (range 28–43). Infectious
complications included three episodes of bacteremia and one
systemic fungal infection (the only death on this regimen). Notable
also were electrolyte disturbances including hyponatremia (50%),
which has been described after bortezomib and vincristine. In one
patient, SIADH may have been the cause of the hyponatremia.
Hypokalemia and dehydration were also observed. Hypophospha-
temia grade 3-4 was seen in two patients but was symptomatic only
in the one patient described above, which was associated with
rhabdomyolysis and subsequent mental status changes. Significant
neurologic events included: confusion and myositis secondary to
rhabdomyolysis from hypophosphatemia; depressed sensorium
secondary to dehydration that recovered after fluids; cerebral
ischemia from small acute cortical infarctions secondary to PEG-
asparaginase, which was then discontinued; and syncope that
resolved with no intervention. Interestingly, two patients had mild
peripheral neuropathy (grades 1 and 2), requiring no intervention,
such as therapy interruption or dose modification. There was no
discernible difference in the distribution of toxicity reporting
between dose levels 1 and 2.
Efficacy
Nine patients are evaluable for response. Six patients achieved a
CR (67%), and an additional one patient achieved a CR in the bone
marrow but had persistent CNS leukemia (patient did not receive
weekly intrathecal triple chemotherapy, which was introduced
thereafter). Therefore, 7/9 (78%) achieved a bone marrow CR. One
patient achieved SD and another patient died on day 17 before
response could be evaluated. Of patients in first relapse, 3/4 (75%)
Pediatr Blood Cancer DOI 10.1002/pbc
TABLE III. Grades 3–5 Toxicity Data in the 10 Patients Evaluable for Toxicity
Group Toxicity Grade 3 Grade 4 Grade 5 Total
Hematologic Hemoglobin 6 1 7
Neutropenia 7 7
Lymphopenia 1 1
Leukopenia 1 8 9
Thrombocytopenia 8 8
Infectious Febrile Neutropenia 4 4
Implant site Infection 1 1
Infection with neutropenia 3 1 4
Pyrexia 1 1
Laboratory Hyperglycemia 3 3
Hypoalbuminemia 1 1
Hypocalcemia 1 1
Hypokalemia 2 1 3
Hyponatremia 5 5
Hypophosphatemia 1 1 2
Neurologic Confusion and myositis 1 1
Depressed Sensorium 1 1
Cerebral ischemia 1 1
Myalgia 1 1
Syncope 1 1
Hepatic/pancreas ALT 3 3
AST 1 1
Lipase 1 1
Coagulation PT, PTT 3 3
Cardiovascular Prolonged QT interval 1 1
Gastrointestinal Abdominal pain 1 1
Caecitis (typhlitis) 1 1
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had bone marrow CR, and of patients in second relapse 4/5 (80%)
had bone marrow CR (Table IV). This level of response, met criteria
to proceed to the phase II part of this study, which is accruing
patients at this time.
DISCUSSION
This phase I study in childhood ALL was designed to evaluate
whether combining bortezomib with a previously active chemo-
therapy backbone is tolerable. It demonstrated that a standard dose
of bortezomib 1.3 mg/m2 given on days 1, 4, 8, and 11 can be safely
combined with an intensive 4-drug reinduction regimen in children
with relapsed ALL. Since the phase I pediatric study of single agent
bortezomib established 1.3 mg/m2 as the MTD [13], we opted for no
further dose escalation in the combination trial. Similarly, in adults
with AML, bortezomib 1.5 mg/m2 on the same schedule was safely
combined with idarubicin and cytosine arabinoside [16].
There was no prolonged bone marrow suppression from this
regimen, even though thrombocytopenia is well recognized after
bortezomib administration. As previously described [3], infections
are common with a similar chemotherapy backbone and can lead
to death from fungal infection. Although both bortezomib and
vincristine can induce peripheral neuropathy only two patients
suffered grade 1-2 transient peripheral neuropathy. However, four
significant neurologic events (confusion, depressed sensorium,
cerebral ischemia, and syncope, Table III) were ascribed to the other
chemotherapy agents. Patients on the phase II portion of the study
receive close monitoring for neurologic toxicity. Pulmonary
toxicity, described after bortezomib use in adults [18], was not
observed in this study.
Interestingly, three of four patients in first relapse achieved a
complete response (CR), but more significantly, four of five
in second relapse achieved complete bone marrow response
(Table IV). This is a higher response rate than the 44% CR
after second relapse reported by Ko et al. [4] Determining remission
reinduction rates in an expanded number of patients in second or
above relapse is the primary objective of the phase II part of the
study. Although early, this level of response is impressive because
very limited single agent bortezomib activity was seen in leukemia
in adults [12] and children [13]. If confirmed in the phase II part of
this study, it may corroborate the in vitro synergistic activity with
dexamethasone [14] as well as the clinical activity previously
observed in one patient [15].
The phase II of this combination is accruing patients with greater
than or equal to second relapse and will include the cohort of patients
in second relapse reported here. Additionally, the data reported
here were used by the COG to initiate another phase II study of
bortezomib with 4-drug induction in early first bone marrow relapse.
The mechanism by which proteasome inhibition leads to
increased sensitivity to chemotherapeutic agents is not clear. It
was previously shown that inhibition of NF-kB, which is
constitutively elevated in leukemia cells, enhances the sensitivity
of AML cells to chemotherapeutic agents [19]. In contrast,
inhibition of NF-kB expression did not enhance chemosensitivity
of ALL cell-lines [20]. Whether bortezomib-induced inhibition
of NF-kB is the primary mechanism inducing leukemia cell death
in vivo is uncertain. In the single agent trial of bortezomib, Horton
et al. [13] observed increased NF-kB expression 6–12 hr after
bortezomib exposure, followed by a 4–6-fold decrease in NF-kB
expression 24 hr after bortezomib exposure. In contrast, Attar et al.
reported in vivo reduction of NF-kB expression within 1 hr after
bortezomib [16]. Bortezomib was shown to down-regulate IkB
expression and trigger NF-kB activation in multiple myeloma,
raising questions about the prevailing model that bortezomib is an
NF-kB inhibitor [21]. Others describe that proteasome inhibition
results in accumulation of Bax and Bim pro-apoptotic proteins,
which sensitize leukemia cells to anthracycline-induced apoptosis
[22]. Elucidation of the specific pathways involved may allow for
additional targeted agents to be used in combination with
bortezomib in the hope of sparing some of the chemotherapy agents
used in the current regimen.
In summary, this phase I study of bortezomib given in standard
twice-weekly doses of 1.3 mg/m2/dose, combined with vincristine,
dexamethasone, PEG-asparaginase, and doxorubicin is tolerable
and shows promising activity in relapsed childhood ALL.
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